Published

EE341 COST-EFFECTIVENESS OF PSILOCYBIN-ASSISTED THERAPY (PAT) FOR PATIENTS WITH TREATMENT-RESISTANT DEPRESSION

No abstract is available for this record.

Open source BibTeX RIS

Bibliographic context

Journal: Value in Health
Date: 2026-05-31
Source: OpenAlex
DOI: 10.1016/j.jval.2026.03.635
PubMed: Unavailable

Authors

Yosr Ziadi Taehwan Park

Watch author

Topics and keywords

psilocybin Depression Personality Change Treatment-Resistant Depression Other Medicine Depression (economics)Internal medicine MEDLINE Psychiatry Text mining Pediatrics Intensive care medicine Physical therapy Psychological therapy Schizophrenia research and treatment Personality Disorders and Psychopathology Medication Adherence and Compliance

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

EE341 COST-EFFECTIVENESS OF PSILOCYBIN-ASSISTED THERAPY (PAT) FOR PATIENTS WITH TREATMENT-RESISTANT DEPRESSION2026-05-31

Related papers

Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17 Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialPLoS Medicine · 2025-09-18 Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysisThe International Journal of Psychiatry in Medicine · 2025-04-24 The psychedelic renaissance: can psilocybin possibly combat depression?International Journal of Surgery Global Health · 2022-10-31 PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trialPalliative Medicine · 2026-01-29 Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 StudyPsychedelic Medicine · 2026-01-17 Psilocybin reporting in media (PRiMe) for the treatment of depressionIrish Journal of Psychological Medicine · 2025-12-17 Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatmentEClinicalMedicine · 2025-11-30